Kevin Bruns, AMCP, kbruns@amcp.org, 703-683-8416, ext. 656
Danielle Mroz, ISPOR, dmroz@ispor.org, 609-586-4981, ext. 112
Andrea Hofelich, NPC, ahofelich@npcnow.org, 202-827-2078

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers in evaluating certain types of comparative effectiveness research (CER) studies. The articles, developed by CER Collaborative members Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the National Pharmaceutical Council (NPC), describe how to assess the credibility and relevance of individual research studies for making coverage and reimbursement decisions.

Members of the CER Collaborative recognized that the growing availability of new research methods poses challenges and opportunities for today’s formulary decision-makers. There is little guidance on how to evaluate and use these new studies, creating a risk for two undesirable outcomes: new study data being misinterpreted or critical information not being used to inform decision-making.

To address those challenges, the CER Collaborative developed a series of questionnaires to guide decision-makers in reviewing studies, which are outlined in the following articles:

These articles were published in the March/April issue (Vol.17 Iss.2) of Value in Health, ISPOR’s official peer-reviewed journal.

An online toolkit (www.cercollaborative.org) incorporating the three questionnaires also assists decision-makers as they assess and incorporate CER studies with other types of evidence for coverage and reimbursement decisions.  

“The rapid introduction of new medicines, especially specialty drugs, makes it imperative that formulary decision-makers evaluating comparative effectiveness have the right tools to reach the most reliable results,” said AMCP CEO Edith A. Rosato, RPh, IOM. “The potential to improve health outcomes and health care affordability is enormous.”

The CER Collaborative’s online toolkit has two main components:

  • Assessing the Evidence: An Individual Study—Three articles and an online tool help users determine whether a study is relevant and credible enough to include in the formulary decision-making process. The online tool helps decision-makers make that assessment for four types of research studies: prospective and retrospective observational studies, indirect treatment comparisons or network meta-analyses, and modeling studies.
  • Synthesizing a Body of Evidence: Multiple Studies—Formulary decisions require rigorous evaluation of the body of evidence, which may include different study designs, each with strengths and limitations. The online guided review of the evidence empowers the decision-makers with the tools to consistently and transparently assess the comparative benefits and risks of therapies and the corresponding certainty of evidence.

Both components of the toolkit provide abundant links to background information and include user “helper” questions, tangible examples, frequently asked questions and glossaries. The CER Collaborative also will be discussing the toolkit at AMCP’s Annual Meeting on Thursday, April 3, 2014 from 2:45 pm–4:00 pm. Incorporating Comparative Effectiveness Research Knowledge and Tools into Practice: Three Perspectives will discuss how the tool is being used in pharmacy and therapeutics (P&T) committees, academia, and the pharmaceutical industry.

“These reports and online tools serve as a platform to assist the health care decision-making community in the use of observational, modeling, and indirect treatment comparison studies in their deliberations. The goal of this collaborative effort is to educate both the producers (researchers) and users (health care decision-makers) of health care evidence.” said Marilyn Dix Smith, RPh, PhD, Founding Executive Director, ISPOR.

“Understanding how treatments work in the real world is an important but complex task.  Collaborative dialogues across all stakeholders help to ensure that meaningful and usable research is generated to guide decision-making,” said Dan Leonard, NPC President.

About the Academy of Managed Care Pharmacy (AMCP)
The Academy of Managed Care Pharmacy is a national professional association of pharmacists and other health care practitioners who serve society by the application of sound medication management principles and strategies to improve health care for all. The Academy's nearly 7,000 members develop and provide a diversified range of clinical, educational and business management services and strategies on behalf of the more than 200 million Americans covered by a managed care pharmacy benefit. www.amcp.org

About the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) promotes the science of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being including clinical, economic, and patient-centered outcomes) and facilitates the translation of this research into useful information for health care decision makers to increase the efficiency, effectiveness, and fairness of health care to improve health. For more information, please see: www.ispor.org and follow ISPOR on Twitter: @ISPORorg.

About the National Pharmaceutical Council (NPC)
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information visit www.npcnow.org and follow NPC on Twitter @npcnow.

Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
Press Release

Data Can Offer Critical Insights, But Roadblocks to Data Access Persist

(Washington, D.C., April 1, 2016)—Data is key to improving health outcomes and creating efficiencies in our health care system, but a new study...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Press Release

Data Can Offer Critical Insights, But Roadblocks to Data Access Persist

(Washington, D.C., April 1, 2016)—Data is key to improving health outcomes and creating efficiencies in our health care system, but a new study...
Press Release

Fit for Purpose? New NPC, AcademyHealth Framework Closes Gaps Between Payer Needs and Research Answers

(Washington, DC, September 21, 2015)—Despite multi-million dollar public and private investments to tap into big data and improve the evidence...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

When Is Evidence Fit for Purpose? Closing Gaps Between Researchers, Payers

Despite multi-million dollar public and private investments to tap into big data and improve the evidence available for health care decision-making,...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Blog Post

Key Considerations for Cost Effectiveness Thresholds

While putting a price tag on the value of health care services and the life years gained is common in countries including the United Kingdom, Canada...
Blog Post

CER Tweets of the Week: JCER Editorial on Treatment Sequences in Oncology; JNCCN Discusses CER Database Analyses (December 14-18, 2015)

What were comparative effectiveness research (CER) stakeholders talking about on Twitter this week? Popular topics included the Journal of...
Blog Post

#TBT: CER Collaborative & Environmental Trends

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...

Data, Data Everywhere, But Access Remains a Big Issue for Researchers

This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...

Standards and Guidelines for Observational Studies: Quality Is in the Eye of the Beholder

The lack of observational study standard/guideline agreement may contribute to variation in study...
  •  
  • 1 of 16
  • >